Acupuncture for Cancer Related Pain: Protocol for a Pragmatic Randomised Wait-List Controlled Trial.
Study Goal
The researchers aimed to assess the effectiveness and safety of acupuncture for managing cancer-related pain in a real-world setting and to understand patients' experiences with the treatment.
Results Summary
The study hypothesized that acupuncture would relieve cancer-related pain at mid-treatment and post-treatment, with few adverse events. However, the abstract does not provide specific results, only expected outcomes.
Population
Adults with cancer-related pain in South Western Sydney Local Health District, Australia (n=106).
Effective Dosage
Not specified
Duration
4 weeks (waitlist period)
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
acupuncture | decrease | cancer related pain (CRP) | in China, America and some other countries | - | has been proved effective | #1 |
acupuncture | decrease | cancer related pain | Adults with cancer related pain (n = 106) | - | will relieve | #2 |
acupuncture | no change | adverse events | Adults with cancer related pain (n = 106) | few | few adverse events will be provoked | #3 |
BACKGROUND: Acupuncture has been proved effective for cancer related pain (CRP) in China, America and some other countries. However, there is relative lack of evidence to support the use of acupuncture for CRP in Australia. OBJECTIVES: To assess the effectiveness and safety of acupuncture for management of CRP in a real-world setting and to understand cancer patients' experience of undergoing acupuncture for CRP. METHODS: A pragmatic randomised controlled trial will be conducted in South Western Sydney Local Health District (SWSLHD) in NSW, Australia. Adults with cancer related pain (n = 106) will be randomised in a 1:1 ratio to receive the acupuncture intervention up front versus after a wait list period of 4 weeks. Pain level (by Numerical Rating Scale), analgesic use, auricular acupressure frequency and adverse events will be assessed at baseline, mid-treatment and post-treatment. Expectancy on trial outcome (by Credibility and Expectancy questionnaire) will be assessed at baseline. The perspective of the participants (by an interview) will be recorded after the last intervention. EXPECTED OUTCOMES: We hypothesise that acupuncture will relieve cancer related pain at mid-treatment and post-treatment. We also hypothesise that few adverse events will be provoked by acupuncture. TRIAL REGISTRATION: Australia New-Zealand Clinical Trial Registry (ACTRN12620000325909).